The camptothecins

Lancet

Volumn 361, Issue 9376, 2003, Pages 2235-2242

  Pizzolato, Joseph F ^a   Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ACETORPHAN; AFELETECAN; ANTINEOPLASTIC AGENT; ATROPINE; CAMPTOTHECIN; CARBOPLATIN; CARBOXYLIC ACID; CASPASE; CISPLATIN; COLONY STIMULATING FACTOR; CYCLOOXYGENASE 2 INHIBITOR; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DRUG METABOLITE; ETOPOSIDE; EXATECAN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LACTONE; LOPERAMIDE; NEOMYCIN; PACLITAXEL; RUBITECAN; TOPOTECAN;

APOPTOSIS; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CAMPTOTHECA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMICAL MODIFICATION; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DNA CLEAVAGE; DNA HELIX; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG TARGETING; DRUG USE; FLUSHING; GASTROINTESTINAL CARCINOMA; GILBERT DISEASE; GRANULOCYTOPENIA; HEMORRHAGIC CYSTITIS; HUMAN; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; MUSCLE CRAMP; NEUTROPENIA; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCIENCE; SWEATING;

EID: 0038167666     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13780-4     Document Type: Review

References (93)

1. Wall M.E., Wani M.C., Cook C.E., Palmer K.H. Plant antitumor agents, I: the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 88:1966;3888-3890.
2. Moertel C.G., Schutt A.J., Reitemeier R.J., Hahn R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep. 56:1972;95-101.
3. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 260:1985;14873-14878.
4. Hsiang Y.H., Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1988;1722-1726.
5. Schneider E., Hsiang Y.H., Liu L.F. DNA topoisomerases as anticancer drug targets. Adv Pharmacol. 21:1990;149-183.
6. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:1989;5077-5082.
7. Sane A.T., Bertrand R. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death. Cancer Res. 59:1999;3565-3569.
8. Li L.H., Fraser T.J., Olin E.J., Bhuyan B.K. Action of camptothecin on mammalian cells in culture. Cancer Res. 32:1972;2643-2650.
9. Sugimoto Y., Tsukahara S., Oh-hara T., Isoe T., Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50:1990;6925-6930.
10. Giovanella B.C., Stehlin J.S., Wall M.E., et al. DNA topoisomerase I: targeted chemotherapy of human colon cancer in xenografts. Science. 246:1989;1046-1048.
11. Husain I., Mohler J.L., Seigler H.F., Besterman J.M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 54:1994;539-546.
12. Kingsbury W.D., Boehm J.C., Jakas D.R., et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem. 34:1991;98-107.
13. Houghton P.J., Cheshire P.J., Myers L., Stewart C.F., Synold T.W., Houghton J.A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol. 31:1992;229-239.
14. Friedman H.S., Houghton P.J., Schold S.C., Keir S., Bigner D.D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 34:1994;171-174.
15. Pratesi G., Tortoreto M., Corti C., Giardini R., Zunino F. Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Br J Cancer. 71:1995;525-528.
16. Verweij J., Lund B., Beijnen J., et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol. 4:1993;673-678.
17. Saltz L., Sirott M., Young C., et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst. 85:1993;1499-1507.
18. Hochster H., Liebes L., Speyer J., et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol. 12:1994;553-559.
19. Beran M., Kantarjian H. Topotecan in the treatment of hematologic malignancies. Semin Hematol. 35:(3 suppl 4):1998;26-31.
20. Kindler H.L., Kris M.G., Smith I.E., et al. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. Am J Clin Oncol. 21:1998;438-441.
21. Mainwaring P.N., Nicolson M.C., Hickish T., et al. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer. 76:1997;1636-1639.
22. Macdonald J.S., Benedetti J.K., Modiano M., Alberts D.S. Phase II evaluation of topotecan in patients with advanced colorectal cancer: a Southwest Oncology Group trial (SWOG 9241). Invest New Drugs. 15:1997;357-359.
23. Creemers G.J., Wanders J., Gamucci T., et al. Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. Ann Oncol. 6:1995;844-846.
24. Saltz L.B., Schwartz G.K., Ilson D.H., Quan V., Kelsen D.P. A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. Am J Clin Oncol. 20:1997;621-625.
25. ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 15:1997;2183-2193.
26. Simpson A.B., Calvert P.M., Sludden J.A., et al. Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. Ann Oncol. 13:2002;399-402.
27. Bookman M.A. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Semin Oncol. 29:(1 suppl 1):2002;20-31.
28. Gerrits C.J., Burris H., Schellens J.H., et al. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer. 34:1998;1030-1035.
29. Clarke-Pearson D.L., Van Le L., Iveson T., et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol. 19:2001;3967-3975.
30. Gore M., Oza A., Rustin G., et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer. 38:2002;57-63.
31. Schiller J.H., Adak S., Cella D., DeVore R.F. III, Johnson D.H. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593: a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 19:2001;2114-2122.
32. Ardizzoni A., Hansen H., Dombernowsky P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol. 15:1997;2090-2096.
33. Schiller J.H., Kim K., Hutson P., et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol. 14:1996;2345-2352.
34. von Pawel J., Gatzemeier U., Pujol J.L., et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 19:2001;1743-1749.
35. Ohe Y., Sasaki Y., Shinkai T., et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst. 84:1992;972-974.
36. Negoro S., Fukuoka M., Masuda N., et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 83:1991;1164-1168.
37. Kawato Y., Aonuma M., Hirota Y., Kuga H., Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51:1991;4187-4191.
38. Gupta E., Lestingi T.M., Mick R., Ramirez J., Vokes E.E., Ratain M.J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54:1994;3723-3725.
39. Gupta E., Wang X., Ramirez J., Ratain M.J. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 39:1997;440-444.
40. Wasserman E., Myara A., Lokiec F., et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol. 8:1997;1049-1051.
41. Iyer L., Das S., Janisch L., et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2:2002;43-47.
42. Kaneda N., Yokokura T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res. 50:1990;1721-1725.
43. Rothenberg M.L., Kuhn J.G., Burris H.A. III, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 11:1993;2194-2204.
44. Rowinsky E.K., Grochow L.B., Ettinger D.S., et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 54:1994;427-436.
45. Kawato Y., Furuta T., Aonuma M., Yasuoka M., Yokokura T., Matsumoto K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol. 28:1991;192-198.
46. Chabot G.G., Abigerges D., Catimel G., et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol. 6:1995;141-151.
47. Conti J.A., Kemeny N.E., Saltz L.B., et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 14:1996;709-715.
48. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418.
49. Rougier P., Van Cutsem E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412.
50. Abigerges D., Armand J.P., Chabot G.G., et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst. 86:1994;446-449.
51. Saliba F., Hagipantelli R., Misset J.L., et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol. 16:1998;2745-2751.
52. Baumer P.H., Danquechin-Dorval E., Bertrand J., Vetel J.M., Schwartz J.C., Lecomte J.M. Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhea. Gut. 33:1992;753-758.
53. Blanke CD, Benson AB III, Dragovich T, et al. A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC). Proceedings of the American Society of Clinical Oncology 2002: abstract 505. Available at http://www.asco.org .
54. Kehrer D.F., Sparreboom A., Verweij J., et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res. 7:2001;1136-1141.
55. Shimada Y., Yoshino M., Wakui A., et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol. 11:1993;909-913.
56. Parnes H.L., Tait N., Conley B., et al. A phase I study of CPT-11, weekly bolus 5-FU and leucovorin in patients with metastatic cancer. Oncol Rep. 2:1995;1131-1134.
57. Saltz L.B., Kanowitz J., Kemeny N.E., et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol. 14:1996;2959-2967.
58. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 343:2000;905-914.
59. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 355:2000;1041-1047.
60. Hennin KC, Thuss-Patience P, Catane R, et al. Final results of a phase II trial of CPT-11 in patients with advanced gastric cancer. Proceedings of the American Society of Clinical Oncology 1999: abstract 258. Available at http://www.asco.org .
61. Kano Y., Suzuki K., Akutsu M., et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 50:1992;604-610.
62. Masumoto N., Nakano S., Esaki T., et al. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res. 15:1995;405-409.
63. Fukuda M., Nishio K., Kanzawa F., et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. 56:1996;789-793.
64. Saltz L.B., Spriggs D., Schaaf L.J., et al. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol. 16:1998;3858-3865.
65. Ilson D.H., Saltz L., Enzinger P., et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 17:1999;3270-3275.
66. Ilson D.H., Minsky B., Kelsen D. Irinotecan, cisplatin, and radiation in esophageal cancer. Oncology (Huntingt). 16:(5 suppl 5):2002;11-15.
67. Boku N., Ohtsu A., Shimada Y., et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 17:1999;319-323.
68. Wagener D.J., Verdonk H.E., Dirix L.Y., et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol. 6:1995;129-132.
69. Rocha Lima C.M., Savarese D., Bruckner H., et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 20:2002;1182-1191.
70. Date H., Kiura K., Ueoka H., et al. Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer. Br J Cancer. 86:2002;530-533.
71. Masuda N, Fukuoka M, Negoro S, et al. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC): a multicenter phase III study. Proceedings of the American Society of Clinical Oncology 1999. Available at http://www.asco.org .
72. Niho S, Nagao K, Nishiwaki Y, et al. Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology 1999. Available at http://www.asco.org .
73. Noda K., Nishiwaki Y., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 346:2002;85-91.
74. Perez EA, Hillman DW, Mailliard JA, et al. Randomized phase II study of 2 schedules of irinotecan (CPT-11) for patients (pts) with refractory metastatic breast cancer (MBC): an NCCTG Cooperative Group study. Proceedings of the American Society of Clinical Oncology 2002: abstract 206. Available at http://www.asco.org .
75. Pazdur R., Diaz-Canton E., Ballard W.P., et al. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol. 15:1997;2905-2909.
76. Saltz L.B., Kemeny N.E., Tong W., Harrison J., Berkery R., Kelsen D.P. 9-aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer. 80:1997;1727-1732.
77. Pitot H.C., Knost J.A., Mahoney M.R., et al. A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer. 89:2000;1699-1705.
78. Vokes E.E., Gordon G.S., Rudin C.M., et al. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs. 19:2001;329-333.
79. Siu L.L., Oza A.M., Eisenhauer E.A., et al. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. J Clin Oncol. 16:1998;1122-1130.
80. Verschraegen C.F., Gupta E., Loyer E., et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs. 10:1999;375-383.
81. Raymond E., Campone M., Stupp R., et al. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer. 38:2002;1348-1350.
82. Ellerhorst J.A., Bedikian A.Y., Smith T.M., Papadopoulos N.E., Plager C., Eton O. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drugs. 13:2002;169-172.
83. Stehlin J.S., Giovanella B.C., Natelson E.A., et al. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol. 14:1999;821-831.
84. Rowinsky E.K., Johnson T.R., Geyer C.E. Jr, et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol. 18:2000;3151-3163.
85. Sharma S., Kemeny N., Schwartz G.K., et al. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 7:2001;3963-3970.
86. Royce M, Saltz LB, Rowinsky EK, et al. A phase II study of intravenous exatecan mesylate (Dx-8951f, Dx) administered daily for five days every three weeks to patients with advanced or metastatic adenocarcinoma of the colon or rectum. Proceedings of the American Society of Clinical Oncology 2000: abstract 1129. Available at http://www.asco.org .
87. D'Adamo D, Hammond LA, Donehower R, et al. Final results of a phase II study of DX-8951f (exatecan mesylate, DX) in advanced pancreatic cancer. Proceedings of the American Society of Clinical Oncology 2001: abstract 532. Available at http://www.asco.org .
88. Abou-Alfa GK, O'Reilly EM, Rowinsky EK, et al. Final results of a phase II study of DX-8951f (DX, exatecan mesylate) in biliary tree cancers. Proceedings of the American Society of Clinical Oncology 2002: abstract 561. Available at http://www.asco.org .
89. O'Reilly E, Hammond LA, Sharma S, et al. A phase II study of exatecan mesylate (DX-8951F, DX) in advanced pancreatic cancer. Proceedings of the American Society of Clinical Oncology 2000: abstract 1170. Available at http://www.asco.org .
90. O'Reilly EM, Hoff PM, Mani S, et al. A phase I study of DX-8951f (exatecan mesylate, DX) and gemcitabine (Gem) in advanced solid tumors. Proceedings of the American Society of Clinical Oncology 2001: abstract 412. Available at http://www.asco.org .
91. de Jonge M.J., Punt C.J., Gelderblom A.H., et al. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol. 17:1999;2219-2226.
92. Siu LL, Batist G, Bangash N, et al. A phase I study of BAY 38-3441 given as a short infusion daily for five days every 3 weeks: a National Cancer Institute of Canada Clinical Trials Group study. Proceedings of the American Society of Clinical Oncology 2002: abstract 395. Available at http://www.asco.org .
93. Mross K, Sauer U, Haring B, et al. A phase I dose escalation pharmacokinetic (PK) study of BAY 38-3441 administered as a short infusion once every three weeks. Proceedings of the American Society of Clinical Oncology2002: abstract 396. Available at http://www.asco.org .